

June 23, 1970

Dr. Sudheer Gogte
3/37 All India Institute
of Medical Sciences
New Delhi 16, India

Dear Dr. Gogte:

Separately I am sending the reprints you requested.

Our college has a formal course in pharmacology leading to a Ph.D. degree. It is not a clinical program however, In this country, the clinical programs that are well known are at Vanderbilt University (Dean, School of Medicine, Nashville, Tennessee) and the University of Michigan (Dean, University of Michigan School of Medicine, Ann Arbor, Michigan).

I have asked our Director of Residence Training to send you the applications requested.

As to the cyclazocine report, we selected imipramine failures since: (1) cyclazocine was an experimental treatment; (2) the only justification for its ethical application lies in trials in those who fail other treatments.

We have discontinued these studies because cyclazocine is no longer available for experimental trial in depression. It was concluded, that despite its antidepressant activity, cyclazocine was associated with sufficient secondary effects as to preclude its usefulness in mass trials. We are interested in homologs of cyclazocine. Now, and these should be brought to clinical trial in the next few years.

Thank you for your careful inquiry.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:kk